About Ironwood Pharma
Ironwood Pharma is a publicly listed company based in Cambridge (United States) founded in 1998. Therapeutics for gastrointestinal disorders, including linaclotide, are developed. Ironwood Pharma has raised $206.25 million across 8 funding rounds from investors including Morgan Stanley, Ridgeback Capital Management and Invus. The company has 253 employees. Ironwood Pharma has completed 1 acquisition, including VectivBio. Its chief executive, as recorded, is Thomas Mccourt. Its website ironwoodpharma.com draws about 21 thousand monthly visits. Ironwood Pharma offers products and services including LINZESS. Its focus areas include Life Sciences, Gastroenterology, Drugs and Diversified. Its competitors include Alcresta, Seed and Ardelyx; 3 of its 3 listed competitors have raised funding.
Company details
Ironwood Pharma was founded in 1998 in Cambridge, United States, within the pharmaceutical sector. Focus is placed on developing treatments for gastrointestinal conditions. Linaclotide, the lead product, acts as a guanylate cyclase-C agonist and is approved for irritable bowel syndrome with constipation as well as chronic idiopathic constipation. Provisions for pediatric gastrointestinal diseases are also included in the portfolio.
- Headquarters Cambridge, United States
- Employees 253
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website ironwoodpharma.com
- Social LinkedIn X
- Legal Name Ironwood Pharmaceuticals, Inc.
- Annual Revenue$296.15 M (USD)-15.72as on Dec 31, 2025
- Net Profit$24.02 M (USD)2629.2as on Dec 31, 2025
- EBITDA$120.64 M (USD)23.44as on Dec 31, 2025
- Total Equity Funding$206.25M (USD)
in 8 rounds
- Latest Funding Round$341M (USD), Post-IPO
Aug 2019
- InvestorsMorgan Stanley
& 8 more
- Employee Count253
- Investments & Acquisitions
Products & Services of Ironwood Pharma
Ironwood Pharma offers a comprehensive portfolio of products and services, including LINZESS.
Medication for treating gastrointestinal diseases and symptoms.
Funding Insights of Ironwood Pharma
Ironwood Pharma has successfully raised a total of $206.25M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $341 million completed in August 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $206.25M
- Total Rounds 8
- Last Round Post-IPO — $341M
- First Round $26M
(Apr 2002)
- Investors Count 9
All 8 funding rounds of Ironwood Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2019 | $341M | Post-IPO | – | – | – |
| Nov 2009 | $15M | Series F | – | – | – |
| Sep 2009 | $25M | Series F | – | – | – |
| Aug 2009 | $249,996 | Series F | – | – | – |
| Oct 2008 | $50M | Series F | – | – | |
| Jun 2007 | $50M | Series E | – | – | – |
| May 2004 | $40M | Series D | – | – | |
| Apr 2002 | $26M | Series C | – | – |
9 investors in total: 9 institutional.
Investors in Ironwood Pharma
Ironwood Pharma has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Morgan Stanley, Ridgeback Capital Management and Invus.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Long-term private equity investments in transformational opportunities are pursued. | invus.com | New York, United States | ||
Government-backed investments are directed toward healthcare, fintech, and various sectors. | edbi.com | Singapore, Singapore | ||
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
US focused venture capital firm | polarispartners.com | Boston, United States | ||
US Life-Sciences sectors are targeted for investment by Aberdare Ventures. | aberdare.com | San Francisco, United States | ||
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | fprimecapital.com | |||
Wealth management, investment advisory, and financial services are provided. | 1935 | morganstanley.com | New York, United States | |
Ridgeback Capital Management is engaged in personal financial planning and investment management. | 2011 | ridgebackcm.com | Bellaire, United States | |
Provides investment strategies for growth and environmental sectors. | 1976 | essexinvest.com | Boston, United States |
Investor details for Ironwood Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Ironwood Pharma
39 people are tracked at Ironwood Pharma (19 in leadership, 8 in board & advisors, 12 in team); the tracked headcount is 253.
| Name | Role | Group |
|---|---|---|
Thomas Mccourt | CEO | Leadership |
Maria Mahmoud | Vice President Of Sales | Leadership |
Jana Noeldeke | Basel Site Head & Apraglutide Lifecycle Leader | Leadership |
Amy Gates | Director, Medical Writing | Leadership |
Daniel Griffin | Head Of Talent Acquisition & Total Rewards | Leadership |
John Minardo | SVP & Chief Legal Officer | Leadership |
Maziar Assadi Gehr | Senior Medical Director | Leadership |
Ron Silver | Senior Vice President, Corporate Controller & Chief Accounting Officer | Leadership |
Ashleigh Arthur | Associate Director, Accounting | Leadership |
Greg Martini | Senior Vice President, Chief Financial Officer | Leadership |
Susanna Y. Huh | Vice President And Head Of Clinical Development | Leadership |
Lara Lane | Director Of Clinical Operations | Leadership |
Jennifer Benson | Senior Director Clinical Outsourcing, Clinical Operations | Leadership |
Jeff Ruberti | Chief Strategy Officer | Leadership |
Thomas Wright | Vice President Manufacturing And Technical Operations | Leadership |
Patrick McKenna | Director, Packaging Operations | Leadership |
Alex Hicks | Sr. Director, Finance | Leadership |
Mai Elhennawy | Director, Clinical Scientist | Leadership |
Michael Shetzline | Chief Medical Officer, SVP & Head of Drug Development | Leadership |
Marla Kessler | Director | Board & advisors |
19 more people are available in the full profile.
Complete people profiles for Ironwood Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Ironwood Pharma
Ironwood Pharma is a publicly listed company on the NASDAQ with ticker symbol IRWD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date03 Feb 2010
- Listed onNASDAQ: IRWD
- Listed entityIronwood Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS46333X1081
- Share price$3.59 (-4.52% on the day) · 2026-10-13
- Market capitalisation$593.2M
- Price to earnings4.7
- EPS (diluted, trailing year)$0.77
- Volume (last session)2,106,375
Financials of Ironwood Pharma
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $296.1M | $24.0M | $120.6M |
| 2024 | $351.4M | $880,000 | $97.7M |
| 2023 | $442.7M | -$1.00B | $210.6M |
| 2022 | $410.6M | $175.1M | $251.8M |
| 2021 | $413.8M | $528.5M | $233.7M |
Detailed financial statements for Ironwood Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ironwood Pharma
Ironwood Pharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include VectivBio.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Transformative therapeutics for rare diseases are developed. | vectivbio.com | Basel, Switzerland | 2019 | May 2023 | $1B |
Complete acquisition details for Ironwood Pharma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Ironwood Pharma
5 dated milestones of Ironwood Pharma across 25 years, from founding to its latest funding, stage changes and deals.
- Founded Ironwood Pharma is founded.
- Funding First funding round of $26.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $341.0M.
- Acquisition Acquires VectivBio.
Competitors of Ironwood Pharma
Ironwood Pharma has 3 listed competitors in our database, 3 of them funded. They include Alcresta, Seed and Ardelyx.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| alcresta.com | 2011 | Newton, United States | $95.89M | 52 | Enzyme-based products for gastrointestinal disorders are developed using immobilization technology. | |
| seed.com | 2016 | Los Angeles, United States | $40.62M | Synbiotics are developed for simulating the gut microbiome. | ||
| ardelyx.com | 2007 | Fremont, United States | $61.1M | 37 | Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. |
Detailed competitors of Ironwood Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Ironwood Pharma
The website of Ironwood Pharma (ironwoodpharma.com) receives about 20.5K visits a month and ranks #2,523,580 among all websites worldwide, #3,466 in Biotechnology and Pharmaceuticals.
- Monthly visits20.5K
▲ 133.1% vs previous month
- Unique visitors3.9K
per month
- Global rank#2,523,580
among all websites
- Category rank#3,466
Health · Biotechnology and Pharmaceuticals
- Bounce rate45%
- Pages per visit1.7
- Average visit16 sec
- DevicesDesktop 45% · Mobile 55%
Websites whose visitors overlap most with Ironwood Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| progenics.com | 100% | View details | |||
ir.achillion.com | ir.achillion.com | 99% | – | ||
| sagentpharma.com | 99% | 16.1K | #1,111,836 | View details | |
investor.anthera.com | investor.anthera.com | 98% | – | ||
| allos.com | 98% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for Ironwood Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Gastroenterology
3 companies that operate in the same segment as Ironwood Pharma (Gastroenterology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | |||
Provider of a deep learning platform for detecting circulating cancer-related markers | 2014 | United States | USD 1.35 B | 411 | ||
Non-invasive biomarker tests for colorectal cancer are developed. | 2015 | St. Louis, Missouri, United States | USD 218.95 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ironwood Pharma
Complete news archive for Ironwood Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ironwood Pharma
Ironwood Pharma was founded in 1998 and raised its 1st funding round 4 years after it was founded.
Ironwood Pharma is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Thomas Mccourt is the CEO of Ironwood Pharma, as recorded in our data.
Ironwood Pharma is a funded company, having raised a total of $206.25M across 8 funding rounds to date. The company's 1st funding round was a Series C of $26M, raised on Apr 2002.
Ironwood Pharma has 253 employees.
Annual revenue of Ironwood Pharma is $296.15M as on Dec 31, 2025.
Ironwood Pharma was founded in 1998 in Cambridge, United States, within the pharmaceutical sector. Focus is placed on developing treatments for gastrointestinal conditions. Linaclotide, the lead product, acts as a guanylate cyclase-C agonist and is approved for irritable bowel syndrome with constipation as well as chronic idiopathic constipation. Provisions for pediatric gastrointestinal diseases are also included in the portfolio.
Ironwood Pharma offers LINZESS.
Yes, Ironwood Pharma is publicly traded on NASDAQ under the ticker symbol IRWD.
Ironwood Pharma has made 1 acquisition, including VectivBio.
Ironwood Pharma has 9 investors. Key investors include Morgan Stanley, Ridgeback Capital Management, Invus, EDBI, and Venrock.